Abstracts » Business

Biotechnology: keep an eye on new faces

Article Abstract:

Management changes in UK biotechnology companies are seen as important for investors. These companies often do not have sales and profit data to aid investors and it is their potential that is attractive, so the manager is crucial. Management changes include Pam Kirby who has moved to help sales and marketing at British Biotech and has come from Astra. This move makes British Biotech more attractive to fund managers. Meanwhile Cantab has appointed Jurek Sikorski as chief executive.

Economic aspects, Management

---

Biotechnology: bouncing babies

Article Abstract:

UK biotechnology companies are enjoying success. Chiroscience has set up an alliance with Pharmacia from Sweden to develop an anaesthetic, and this has led to a rise in Chiroscience's share price. The four biggest UK biotechnology companies are worth some 1.4 billion pounds sterling in 1995, while in 1991 there was not a single UK biotechnology company that was fully quoted. Biotechnology has been aided by developments in the pharmaceutical industry as a whole.

---

Biotechnology companies: out of fashion

Article Abstract:

UK biotechnology companies have become less popular with financial markets and this has affected the share prices of British Biotech, Chiroscience and Celltech. Cambrio has had to cancel a planned flotation. The shares of biotechnology firms had performed exceptionally well in 1st half 1996, but some companies have encountered failures in drug trials. The biotechnology sector is still likely to attract investors due to its importance for large drug firms.

Pharmaceutical industry

Some parts © 2012 Advameg, Inc.